Pharmacytimes: Condition Center: Asthma http://www.pharmacytimes.com/condition-resources/asthma/condition-rss Asthma en-us Sun, 22 Apr 2018 12:30:07 UTC Sun, 22 Apr 2018 12:30:07 UTC Severe Weather and Asthma: A Tumultuous Thunderstorm http://www.pharmacytimes.com/resource-centers/asthma/severe-weather-and-asthma-a-tumultuous-thunderstorm Weather can exacerbate asthma, and one specific trigger is thunderstorm activity. 8:00 AM, Fri April 20, 2018 Pediatric Asthma: Look for these Signs http://www.pharmacytimes.com/resource-centers/asthma/pediatric-asthma-look-for-these-signs Children may have to skip school, be admitted to the hospital, and occasionally, children die from asthma attacks. That's a clear call for better intervention on the part of healthcare providers. 10:33 AM, Wed April 18, 2018 Smart Inhaler Is About to Reach OTC Market http://www.pharmacytimes.com/contributor/timothy-aungst-pharmd/2018/04/smart-inhaler-is-about-to-reach-otc-market Smart Inhalers have been around for awhile, but have been consigned to use primarily in clinical trials. One company is bringing them to the OTC market. 4:18 PM, Fri April 13, 2018 Avoiding Errors With the Newer Inhalers http://www.pharmacytimes.com/publications/issue/2018/March2018/avoiding-errors-with-the-newer-inhalers Several new devices for the administration of inhaled medications have been introduced. 11:00 AM, Tue March 27, 2018 A Breath of Fresh Air: Novel Treatments for Asthma http://www.pharmacytimes.com/resource-centers/asthma/a-breath-of-fresh-air-novel-treatments-for-asthma Novel therapies such as monoclonal antibodies and phenotype-guided treatments are available and clinicians are using them to help patients with severe asthma. 8:00 AM, Fri March 23, 2018 Nitric Oxide: A Potential Marker for Adherence in Asthma? http://www.pharmacytimes.com/resource-centers/asthma/nitric-oxide-a-potential-marker-for-adherence-in-asthma Current treatment options for patients living with asthma include long acting beta-agonists and inhaled corticoid steroids (ICS). While these therapeutic options are effective in a majority of patients, approximately 10% will remain poorly controlled. 8:00 AM, Wed March 21, 2018 Pharmacist-Provided Spirometry: Reducing Barriers to Better Asthma Care http://www.pharmacytimes.com/resource-centers/asthma/pharmacistprovided-spirometry-reducing-barriers-to-better-asthma-care Asthma and chronic obstructive pulmonary disorder are chronic health conditions that need to be properly diagnosed to be managed effectively. 9:39 AM, Wed March 14, 2018 The Smart Inhaler Market: Getting Bigger with New Players http://www.pharmacytimes.com/contributor/timothy-aungst-pharmd/2018/03/the-smart-inhaler-market-getting-bigger-with-new-players More smart inhalers are coming to the US market and pharmacists may see them soon. 8:37 PM, Tue March 6, 2018 Improving Pediatric Asthma Care: Key Questions, Tips for Providers http://www.pharmacytimes.com/resource-centers/asthma/improving-pediatric-asthma-care-key-questions-tips-for-providers Personalized inpatient assessments prior to prescribing asthma therapy to pediatric patients can improve the accuracy and quality of care. 9:57 AM, Tue March 6, 2018 Understanding Asthma: Significant Research Contributions from 2017 http://www.pharmacytimes.com/resource-centers/asthma/understanding-asthma-significant-research-contributions-from-2017 An international team of respiratory disease specialists looked back at 2017 and assembled a review of the current approaches to asthma and chronic obstructive pulmonary disease. 2:00 PM, Mon March 5, 2018 FDA Accepts Dupilumab sBLA for Treatment of Asthma http://www.pharmacytimes.com/resource-centers/asthma/fda-accepts-dupilumab-sbla-for-treatment-of-asthma Sanofi recently announced that the FDA has accepted the supplemental Biologics License Application (sBLA) of dupilumab (Dupixent) for the maintenance treatment of asthma.  10:00 AM, Mon March 5, 2018 Breath-Actuated Aerosol for Asthma Maintenance Launches http://www.pharmacytimes.com/product-news/breathactuated-aerosol-for-asthma-maintenance-launches QVAR RediHaler is now commercially available to patients by prescription in 40 mcg and 80 mcg strengths. 6:55 AM, Sat February 17, 2018 Telemedicine, School-Based Medication Therapy Can Improve Asthma Outcomes http://www.pharmacytimes.com/resource-centers/asthma/telemedicine-schoolbased-medication-therapy-can-improve-asthma-outcomes Children with asthma who receive a combination of telemedicine support and school-based medication therapy may be less likely to need an asthma-related emergency room or hospital visit. 11:37 AM, Mon January 15, 2018 FDA Officials Find No Increased Risk of Serious Outcomes with LABAs Used with ICS http://www.pharmacytimes.com/resource-centers/allergy/fda-officials-finds-no-increased-risk-of-serious-outcomes-with-labas-used-with-ics The results of all trials showed that the use of LABA with ICS does not significantly increase the risk of serious asthma outcomes compared to ICS alone. 1:33 PM, Thu December 21, 2017 Medication Management in Schools: Pharmacist Involvement Can Improve Outcomes http://www.pharmacytimes.com/resource-centers/asthma/medication-management-in-schools-pharmacist-involvement-can-improve-outcomes Between 10% and 20% of students in kindergarten through high school have chronic illness. 8:00 AM, Tue December 5, 2017 The Answer to Preventing Childhood Asthma: Found in Gut Microbes? http://www.pharmacytimes.com/resource-centers/asthma/the-answer-to-preventing-childhood-asthma-found-in-gut-microbes An infant’s sex-specific gut microbiome following maternal asthma during pregnancy may influence their risk of developing childhood asthma. 3:05 PM, Wed November 29, 2017 COPD: Delving Into Inhaler Adherence http://www.pharmacytimes.com/publications/issue/2017/November2017/copd-delving-into-inhaler-adherence Chronic obstructive pulmonary disease (COPD)—irreversible—requires long-term adherence to pharmacotherapies for best outcomes. 12:05 PM, Wed November 22, 2017 FDA OKs Treatment for Severe Eosinophilic Asthma http://www.pharmacytimes.com/product-news/fda-oks-treatment-for-severe-eosinophilic-asthma Officials with the FDA have approved benralizumab (Fasenra, AstraZeneca) for the add-on maintenance treatment of patients with severe eosinophilic asthma aged 12 years and older. 8:00 AM, Wed November 15, 2017 Ensuring Patient Access to Asthma Therapy: Perspectives for Pharmacists http://www.pharmacytimes.com/publications/issue/2017/September2017/R871_September2017 4:56 PM, Tue November 7, 2017 Fish and Fish Oil Equally Protective Against Childhood Asthma? http://www.pharmacytimes.com/resource-centers/asthma/fish-and-fish-oil-equally-protective-against-childhood-asthma 9:00 AM, Thu November 2, 2017